You are here: Home: Audio Program Guide: CCU 1 | 2009: CCU 1 | 2009 Audio
 
  Go to interview with Paulo M Hoff, MD
Go to interview with Heinz-Josef Lenz, MD
Go to interview with Howard S Hochster, MD
Go to interview with Herbert I Hurwitz, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Paulo M Hoff, MD
Clinical Director
Instituto do Cãncer do Estado de São Paulo (ICESP)
University of São Paulo
Executive Director, Hospital Sírio-Libanês
São Paulo, Brazil

  
  Click here to download the entire interview  
Track 1 HORIZON II and III studies of the VEGF tyrosine kinase inhibitor (TKI) cediranib in metastatic colorectal cancer (mCRC)
Track 2 Side effects and tolerability of cediranib
Track 3 AVANT: Adjuvant bevacizumab with CAPOX or FOLFOX4 versus FOLFOX4 alone for CRC
Track 4 Protective effects of bevacizumab on thrombocytopenia and sinusoidal dilatation
Track 5 Initial safety report of NSABP-C-08: Adjuvant FOLFOX6 with or without bevacizumab
Track 6 Bevacizumab and wound healing
Track 7 Potential mechanisms of action of bevacizumab in the micrometastatic disease setting
Track 8 PACCE and CAIRO-2: Combination therapy with an EGFR monoclonal antibody and bevacizumab
Track 9 CRYSTAL: K-ras status and efficacy of first-line FOLFIRI with or without cetuximab in mCRC
Track 10 Combination therapy with VEGF and EGFR monoclonal antibodies with or without chemotherapy in mCRC
Track 11 Treatment algorithm for systemic therapy in patients with resectable hepatic CRC metastases
Track 12 Selection of pre- and postoperative systemic therapy for patients undergoing resection of hepatic metastases
     
Heinz-Josef Lenz, MD
Professor of Medicine and Preventative Medicine
Director, Colorectal Center
Director, GI Oncology Program
USC/Norris Comprehensive Cancer Center
Los Angeles, California

  
  Click here to download the entire interview  
Track 1 Case discussion: A 36-year-old woman with a synchronous primary colon tumor and unresectable, bilobar hepatic metastases
Track 2 ERCC1 and thymidylate synthase as predictors of response to chemotherapy
Track 3 Potential relationship between K-ras status and bevacizumab sensitivity
Track 4 Enhanced efficacy of partnering anti-VEGF therapy with oxaliplatin for patients who have experienced disease progression after irinotecan-based therapy
Track 5 Conversion of hepatic metastases from unresectable to resectable with FOLFIRI and bevacizumab/
cetuximab in CALGB-C80405
Track 6 Defining parameters for resectable colorectal liver metastases
Track 7 Surgical approach for patients with synchronous primary colon and hepatic metastases
Track 8 BOND-2: Cetuximab/bevacizumab with or without irinotecan in irinotecan-refractory mCRC
Track 9 Toxicity and efficacy in PACCE (chemotherapy/bevacizumab with panitumumab) and CAIRO-2 (chemotherapy/bevacizumab with cetuximab)
Track 10 Case follow-up: Repeat perioperative FOLFIRI/bevacizumab/cetuximab for a recurrent hepatic metastasis followed by resection
Track 11 Incidence of high levels of ERCC1 in CRC and response to FOLFIRI
Track 12 Biologic rationale for potential cure from resection of CRC hepatic metastases
Track 13 Translating the paradigm of resection for CRC metastases to the treatment of breast cancer
Track 14 Role of preoperative therapy to elucidate tumor biology in patients with hepatic-only metastases
Track 15 Colon cancer stem cells and mechanisms of chemoresistance and tumor recurrence
Track 16 Use of molecular signatures to tailor individualized treatment for patients with CRC
     
Howard S Hochster, MD
Professor of Medicine and Clinical Pharmacology
NYU Cancer Institute
New York, New York
  
  Click here to download the entire interview  
Track 1 Mechanism of oxaliplatin neurotoxicity: Rationale for treatment with calcium and magnesium
Track 2 CONcePT: Randomized, placebo-controlled trial of calcium/magnesium and intermittent oxaliplatin in mCRC
Track 3 NCCTG-N04C7: Effect of calcium and magnesium on oxaliplatin-induced neurotoxicity in adjuvant CRC
Track 4 Clinical use of prophylactic intravenous calcium and magnesium off protocol
Track 5 Use of “treatment holidays” in the administration of oxaliplatin-based therapy for mCRC
Track 6 Considerations in the design of next generation adjuvant clinical trials in CRC
Track 7 HORIZON II and III studies of the VEGF TKI cediranib in mCRC
Track 8 Novel targets and agents under investigation in CRC
Track 9 Current key questions in rectal cancer research
Track 10 Selection and timing of systemic therapy for patients with potentially resectable, hepatic-only CRC metastases
     
Herbert I Hurwitz, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Clinical Director, Phase I Program
Co-leader, GI Oncology Program
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Potential role of dual antibodies in combination with chemotherapy in the treatment of mCRC
Track 2 Potential impact of K-ras status on efficacy of FOLFOX versus FOLFIRI in mCRC
Track 3 Defining resectability in patients with hepatic-only metastases
Track 4 Selection of a chemotherapy regimen for downstaging potentially resectable hepatic metastases
Track 5 Pre- and postoperative timing for administration of bevacizumab and wound healing
Track 6 Risk factors for chemotherapy/bevacizumab-associated cardiovascular complications
Track 7 Correlation between bevacizumab-associated hypertension and antitumor efficacy
Track 8 Perspective on improved outcome with the use of bevacizumab beyond first disease progression in the BRiTE registry
Track 9 Clinical approach to treatment holidays for patients with mCRC
Track 10 Insulin-like growth factor axis and colorectal cancer
audio